Company intelligence / Profile preview

TenX Keane Acquisition

New York, New York, United Statesprnewswire.com ↗

Ownership: Public · TENK
Development stage: Commercial

Overview

TenX Keane Acquisition was a blank check company that completed a reverse merger with Citius Pharmaceuticals' oncology subsidiary on August 12, 2024, forming Citius Oncology, Inc.[1][8]

Industry: Investors

Drug pipeline

1 asset

LYMPHIR

Commercial

Indications: Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma

Partnerships

Citius Pharmaceuticals

Financials

Market cap: $269.4M
Total revenue: $1.5M
Enterprise value: $259.3M

Beyond the preview

Go deeper on TenX Keane Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TenX Keane Acquisition.

Explore the full profile